

What are the implications of immunopsychiatry to Olmstead compliance for people with Neurodevelopmental and Psychiatric Disorders?

Immunopsychiatry and Olmstead: How Biology and Civil Rights Intersect

Immunopsychiatry reframes many neurodevelopmental and psychiatric disorders as partly immune-mediated conditions. Olmstead and the ADA require that people with disabilities, including serious mental illness and developmental disabilities, receive services in the **most integrated** setting appropriate, with adequate supports. The papers do not discuss this intersection directly, but together they suggest important implications for policy, services, and clinical decision-making.

1. Immunopsychiatry: Rethinking Diagnosis and Treatment

- Immune dysregulation and chronic low-grade inflammation are implicated in schizophrenia, bipolar disorder, depression, autism spectrum disorder and other NDDs, sometimes starting in early development (Bennett & Molofsky, 2019; Pape et al., 2019; Leboyer et al., 2016; Khandaker et al., 2017; Gagliano et al., 2025; Novellino et al., 2020).
- New “immunoneuropsychiatry” frameworks call for **mechanism-based subgroups** and immune-targeted treatments, moving beyond broad syndromic labels (Miller et al., 2025; Pape et al., 2019; Khandaker et al., 2017; Gagliano et al., 2025; Moriarity & Slavich, 2024).

2. Implications for Who Can Live in the Community

- Many people with IDD and co-occurring mental illness can succeed in community settings when services are trauma-informed, person-centered, and skilled in complex behavior and pharmacology (Pinals et al., 2021).
- Older adults and people with SMI are frequently institutionalized (nursing homes, adult homes) even when community living with supports is feasible, raising Olmstead concerns (Burnim, 2015; Flores, 2017; Bartels, 2011).
- Immunopsychiatric advances may improve functioning with better, more precise treatments, potentially expanding the group who can “handle and benefit from” integrated settings, a key Olmstead criterion (Miller et al., 2025; Pape et al., 2019; Leboyer et al., 2016; Khandaker et al., 2017; Gagliano et al., 2025).

3. Service System and Legal Duties Under Olmstead

Integrated Treatment and Community Supports

Issue	Relevance to Olmstead	Citations
Need for robust community MH & IDD services	Failure → unnecessary institutionalization/jail, seen as discrimination	(Burnim, 2015; Pinals et al., 2021; Flores, 2017; O’connor, 2019; Kormann & Petronko, 2004; Mangan & Dennis, 2023; Schwartz et al., 2020)
Complex, immune-related NDD/SMI presentations	Requires sophisticated community teams, not default institutional care	(Bennett & Molofsky, 2019; Pape et al., 2019; Pinals et al., 2021; Leboyer et al., 2016; Khandaker et al., 2017; Gagliano et al., 2025; Novellino et al., 2020)

Issue	Relevance to Olmstead	Citations
Precision / immune-targeted treatments	May be a “reasonable modification” to enable community living	(Miller et al., 2025; Pape et al., 2019; Al-Diwani et al., 2022; Khandaker et al., 2017; Gagliano et al., 2025; Novellino et al., 2020; Moriarity & Slavich, 2024)

FIGURE 1 Links between treatment capacity and integration duties

- Olmstead enforcement has driven expansion of community mental health and housing; approaches vary widely by state (Avila et al., 2021; Flores, 2017; Bartels, 2011; Kormann & Petronko, 2004; Mangan & Dennis, 2023; Schwartz et al., 2020).
- Some argue Olmstead should also constrain **criminalization** of mental illness, treating jail/prison as a form of unnecessary segregation when community services are inadequate (O’connor, 2019).

4. Neurodevelopmental Focus

- Immune/inflammatory mechanisms are increasingly recognized in NDDs and early-onset psychosis/OCD, supporting a **lifespan neurodevelopmental** view (Pape et al., 2019; Gagliano et al., 2025; Novellino et al., 2020).
- Early immune-informed interventions may prevent or mitigate disability, aligning with ADA/Olmstead’s goal of maximizing participation in work, education, and social life (Burnim, 2015; Henderson et al., 2026; Gagliano et al., 2025; Novellino et al., 2020).

Conclusion

Current research does not yet tie immunopsychiatry explicitly to Olmstead, but it strengthens the argument that many people with neurodevelopmental and psychiatric disorders can live in integrated settings if given immune-informed, person-centered care and robust community supports. As immune-based diagnostics and treatments mature, failure to provide them—and to build community systems capable of using them—may increasingly conflict with Olmstead’s mandate to avoid unnecessary institutionalization and segregation.

These search results were found and analyzed using Consensus, an AI-powered search engine for research. Try it at <https://consensus.app>. © 2026 Consensus NLP, Inc. Personal, non-commercial use only; redistribution requires copyright holders’ consent.

References

- Al-Diwani, A., Pillinger, T., & Lennox, B. (2022). Immunopsychiatry in 2021: premise to promise, and back again.. *The lancet. Psychiatry*, 9 1, 11-12. [https://doi.org/10.1016/s2215-0366\(21\)00466-1](https://doi.org/10.1016/s2215-0366(21)00466-1)
- Avila, A., Spaulding, W., & Evans, E. (2021). Olmstead's implementation: Differences in enforcement approaches.. *Psychological services*. <https://doi.org/10.1037/ser0000551>
- Bartels, S. (2011). Commentary: The Forgotten Older Adult With Serious Mental Illness: The Final Challenge in Achieving the Promise of Olmstead?. *Journal of Aging & Social Policy*, 23, 244 - 257. <https://doi.org/10.1080/08959420.2011.579497>
- Bennett, F., & Molofsky, A. (2019). The immune system and psychiatric disease: a basic science perspective. *Clinical & Experimental Immunology*, 197. <https://doi.org/10.1111/cei.13334>

Burnim, I. (2015). The promise of the Americans with Disabilities Act for people with mental illness.. *JAMA*, 313 22, 2223-4. <https://doi.org/10.1001/jama.2015.4015>

Flores, R. (2017). State reform and respect for the rights of the disabled people: A reflection on the Olmstead decision the case of New York state. *Cogent Medicine*, 4. <https://doi.org/10.1080/2331205x.2017.1360542>

Gagliano, A., Cucinotta, F., Giunta, I., Di Modica, I., De Domenico, C., Costanza, C., Germanò, E., & Frankovich, J. (2025). The Immune/Inflammatory Underpinnings of Neurodevelopmental Disorders and Pediatric Acute-Onset Neuropsychiatric Syndrome: A Scoping Review. *International Journal of Molecular Sciences*, 26. <https://doi.org/10.3390/ijms26167767>

Henderson, C., Kotera, Y., Lloyd-Evans, B., Jordan, G., Gerner, M., Salla, A., Kalha, J., Coventry, P., Bojke, L., Hinde, S., & Slade, M. (2026). Social inclusion of people with severe mental illness: a review of current practices, evidence and unmet needs, and future directions. *World Psychiatry*, 25. <https://doi.org/10.1002/wps.70031>

Khandaker, G., Dantzer, R., & Jones, P. (2017). Immunopsychiatry: important facts. *Psychological Medicine*, 47, 2229 - 2237. <https://doi.org/10.1017/s0033291717000745>

Kormann, R., & Petronko, M. (2004). Community inclusion of individuals with behavioral challenges: who supports the careproviders?. *Mental retardation*, 42 3, 223-8. [https://doi.org/10.1352/0047-6765\(2004\)42<223:cioiwb>2.0.co;2](https://doi.org/10.1352/0047-6765(2004)42<223:cioiwb>2.0.co;2)

Leboyer, M., Oliveira, J., Tamouza, R., & Groc, L. (2016). Is it time for immunopsychiatry in psychotic disorders?. *Psychopharmacology*, 233, 1651 - 1660. <https://doi.org/10.1007/s00213-016-4266-1>

Mangan, J., & Dennis, A. (2023). Judicial Threats to Olmstead and the Americans With Disabilities Act.. *Psychiatric services*, appips20230397. <https://doi.org/10.1176/appi.ps.20230397>

Miller, A., Berk, M., Bloch, G., Briquet-Laugier, V., Brouillon, C., Cuthbert, B., Dantzer, R., Davis, M., De Picker, L., Drevets, W., Eyre, H., Hack, L., Harrison, N., Krystal, A., Lombardo, G., Mondelli, V., Pariante, C., Pulvirenti, L., Salvatore, G., Sforzini, L., Świeboda, P., Trivedi, M., & Leboyer, M. (2025). Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.. *Brain, behavior, and immunity*. <https://doi.org/10.1016/j.bbi.2025.01.002>

Moriarty, D., & Slavich, G. (2024). Toward a dynamic immunopsychiatry.. *Brain, behavior, and immunity*. <https://doi.org/10.1016/j.bbi.2024.02.011>

Novellino, F., Sacca, V., Donato, A., Zaffino, P., Spadea, M., Vismara, M., Arcidiacono, B., Malara, N., Presta, I., & Donato, G. (2020). Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases. *International Journal of Molecular Sciences*, 21. <https://doi.org/10.3390/ijms21031115>

O'connor, K. (2019). Olmstead Decision: Can It Be Used to Decriminalize People With Mental Illness?. *Psychiatric News*. <https://doi.org/10.1176/appi.pn.2019.11a14>

Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019). Immunoneuropsychiatry — novel perspectives on brain disorders. *Nature Reviews Neurology*, 15, 317-328. <https://doi.org/10.1038/s41582-019-0174-4>

Pinals, D., Hovermale, L., Mauch, D., & Anacker, L. (2021). Persons With Intellectual and Developmental Disabilities in the Mental Health System: Part 1. Clinical Considerations.. *Psychiatric services*, appips201900504. <https://doi.org/10.1176/appi.ps.201900504>

Schwartz, S., Fleischner, R., Schwartz, A., & Stephens, E. (2020). Realizing the Promise of Olmstead: Ensuring the Informed Choice of Institutionalized Individuals with Disabilities to Receive Services in the Most Integrated Setting. *Journal of Legal Medicine*, 40, 100 - 63. <https://doi.org/10.1080/01947648.2020.1731329>